Hoy es #DíadelTrabajo. Queremos dar las gracias🙏a todas las personas que trabajan en el @IRBBarcelona, por poner tanto esfuerzo y pasión en la ciencia! Gracias a l@s que estas semanas habéis estado al pie del cañón en la lucha contra la #COVID19. #WeAreIRB
Gràcies a tots els #científics i els #tècnics que de forma voluntària han anat a cuidar cada dia els nostres🐀animals i garantir així la nostra #recerca en aquests temps de crisi i confinament. Sense vosaltres l'activitat de l'@IRBBarcelona se n'hagués pogut ressentir. #WeAreIRB
Also thanks to all of you who have made an effort to adapt and continue with your #research, #papers, computational projects, PhD theses... #telework 💻 has more merit if you have the capacity to adapt to new challenges, if you work with true passion. Proud of you all! #WeAreIRB
Gracias al equipo de administración que también se ha adaptado al #teletrabajo para dar el mejor servicio a la #ciencia del @IRBBarcelona y un👏especial para ITS y HR-Health & Safety, que nos han dado toda la información y herramientas para poder seguir adelante💪 #WeAreIRB
• • •
Missing some Tweet in this thread? You can try to
force a refresh
🔬An international consortium, led by #IRBBarcelona & the biotech company @MerusNV, reports the discovery of MCLA-158, the first clinical candidate screened in #organoids targeting 🎯 #cancer#stemcells of solid tumors.
Named Petosemtamab, the antibody MCLA-158 prevents the onset of #metastasis (that is, the spread of #cancer to other vital organs) and slows the growth of primary tumours in experimental models of cancer.
The study also lays the groundwork for the use of #organoids in the #DrugDiscovery process undertaken by pharmaceutical companies.
Organoids are patient-derived samples that can be grown in the laboratory, and they reproduce certain aspects of the tumour compartment.
#IRBScience: Published in @GenomeMedicine, the latest work from the SBNB lab points to the co-occurrence of #cancer driver genes as a key to precision medicine.
The system is called Targeted Cancer Therapy for You (TCT4U), and it's aimed at predicting tumour response to different treatments.💊
It has allowed the identification of a set of complex biomarkers🧬that have now been made available to the medical-scientific community.
(2/4)↘️
"The sum of two or more mutated #Cancer driver genes affects the tumour's response to treatments" says @ptck72, "through this work, we see that studying cancer driver genes as a whole can bring about a great advance towards precision medicine".
@Eduard_puig is one of the committed scientists who recently made an important contribution to the field.
(1/4)
In June, @Eduard_puig, @SoniaCiudad and Natalia Carulla, among others, revealed the specific ensembles of Aβ protein that have the capacity to disrupt the membrane of neurons, causing their death.
@IRBBarcelona coordinates the European Project Evomet to train 15 young scientists and future leaders in metastasis research with the aim to identify therapeutic solutions. The project has received €4 M and will last for four years.
Each of the institutions will host one of the selected young researchers and will train them until they complete their doctorate, except for @IRBBarcelona and @idibell_cat IDIBELL, which will host two predoctoral researchers each.
#IRBScience: The @bbglab publishes "A compendium of mutational cancer driver genes" in @NatureRevCancer, with mportant implications in clinical decision making.
📢568 genes identified with the potential to trigger #cancer!
The study stands on the analysis of the genomes of 28,000 tumours from 66 types of cancer and it's a major update of the #IntOGen platform (intogen.org), aimed at identifying mutational cancer driver genes.
(2/5)
“The compendium of driver genes provides cancer researchers, both in the clinical and basic research setting, with crucial knowledge and it has an important impact on clinical decision-making,” says @nlbigas, head of the @bbglab at @IRBBarcelona and @icreacommunity.